A Phase 2 interventional study of Belimumab 100 mg SC and Belimumab 100 mg SC in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc.. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 27th largest by enrollment, is one of 3 that started in 2008, is one of 8 in phase 2, and was the 8th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is close to the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc. is the lead sponsor of 23 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 25th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2008, is one of 7 in phase 2, and was the 8th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
This clinical trial will evaluate the safety, pharmacokinetics (PK), and effect on biomarkers of repeated subcutaneous (SC) administration of belimumab in subjects with SLE. As data permit, an exploratory pharmacodynamic analysis will be performed to evaluate the correlation between belimumab serum exposure, PGA, SELENA SELDAI, and biomarker effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
Drug: Belimumab 100 mg SC
Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
Drug: Belimumab 100 mg SC
Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
Also known as: LymphoStat-B™
Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
Evaluation of the Number of Participants Who Experienced Adverse Events (AEs) During the 24 Week Period.
SEE ALSO ADVERSE EVENTS RESULTS SECTION
Time frame: Up to 24 weeks
Absolute Change From Baseline in CD20+ (Total) B Cells at Week 24
Time frame: Baseline, 24 weeks
Median Percent Change From Baseline in CD20+ (Total) B Cells at Week 24.
Time frame: Baseline, 24 Weeks
Absolute Change From Baseline in CD20+/CD27- (Naive) B Cells at Week 24
Time frame: Baseline, 24 weeks
Median Percent Change From Baseline in CD20+/CD27-(Naive) B Cells at Week 24
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24
Time frame: Baseline, 24 Weeks
Absolute Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24
Time frame: Baseline, 24 Weeks
Mean Serum Belimumab Concentration Levels (Pharmacokinetic [PK]) Over 24 Weeks.
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in IgA at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in IgA at Week 24
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in IgG at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in IgG at Week 24
Time frame: Baseline, 24 Weeks
Absolute Change From Baseline in IgM at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in IgM at Week 24
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24
PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
Time frame: Baseline, 24 Weeks
Mean Percent Change From Baseline in PGA Score at Week 24.
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in the Safety of Estrogen in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare.
Time frame: Baseline, 24 Weeks
Mean Percent Change From Baseline in the SELENA SLEDAI Score at Week 24
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in Complement C3 at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in Compliment C3 at Week 24
Time frame: Baseline, 24 Weeks
Absolute Change From Baseline in Complement C4 at Week 24
Time frame: Baseline, 24 weeks
Median Percent Change From Baseline in Complement C4 at Week 24
Time frame: Baseline, 24 Weeks
Absolute Change From Baseline in Anti-Double-Stranded DNA (Anti-dsDNA)at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in Anti-dsDNA at Week 24
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in High Density Lipoproteins (HDL) at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in HDL at Week 24
Time frame: Baseline, 24 week
Absolute Change From Baseline in Total Cholesterol at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in Total Cholesterol at Week 24
Time frame: Baseline, 24 Weeks
Median Percent Change From Baseline in Triglycerides at Week 24
Time frame: Baseline, 24 weeks
Absolute Change From Baseline in Triglycerides at Week 24
Time frame: Baseline, 24 Weeks
| Milestone | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Started | 28 | 28 |
| Completed | 26 | 25 |
| Not completed | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
SEE ALSO ADVERSE EVENTS RESULTS SECTION
| Percentage of participants | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Percent of patients with at least 1 AE | 89.3 | 85.7 |
| Percent of patients with at least 1 Serious AE | 7.1 | 14.3 |
| Percent of patients with an AE resulting in death | 0 | 0 |
| µg/mL | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Mean Serum Belimumab Concentration Levels (Pharmacokinetic [PK]) Over 24 Weeks. | 20.5 ± 11.6 | 120.8 ± 53.7 |
| g/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in IgA at Week 24 | -0.3 ± 0.08 | -0.3 ± 0.10 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in IgA at Week 24 | -8.1 (-45.1 to 15.4) | -10.7 (-36.4 to 34.1) |
| g/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in IgG at Week 24 | -2.2 ± 0.7 | -1.4 ± 0.7 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in IgG at Week 24 | -11.1 (-47.0 to 12.1) | -9.5 (-42.9 to 94.0) |
| g/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in IgM at Week 24 | -0.3 ± 0.04 | -0.4 ± 0.07 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in IgM at Week 24 | -25.6 (-80.0 to 11.0) | -26.9 (-71.6 to 170.6) |
| cells/mm^3 | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in CD20+ (Total) B Cells at Week 24 | -53.5 ± 20.4 | -75.3 ± 23.6 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in CD20+ (Total) B Cells at Week 24. | -33.5 ± 8.88 | -38.2 ± 13.26 |
| cells/mm^3 | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in CD20+/CD27- (Naive) B Cells at Week 24 | -81.9 ± 18.5 | -95.0 ± 20.8 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in CD20+/CD27-(Naive) B Cells at Week 24 | -60.9 ± 6.47 | -66.7 ± 8.0 |
| cells/mL | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24 | 1100.3 ± 389.8 | -77.2 ± 456.9 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24 | 45.2 (-69.6 to 1496.3) | 10.2 (-87.0 to 779.6) |
| cells/mm^3 | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24 | 27.7 ± 6.0 | 19.6 ± 6.2 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24 | 84.2 (-37.5 to 288.9) | 100.0 (-45.5 to 600.0) |
PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
| Scores on a 3-point scale | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24 | -0.4 ± 0.09 | -0.4 ± 0.09 |
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Mean Percent Change From Baseline in PGA Score at Week 24. | -26.1 ± 6.6 | -24.8 ± 13.1 |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare.
| Points on a scale | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in the Safety of Estrogen in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24 | -2.9 ± 0.8 | -3.1 ± 0.5 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Mean Percent Change From Baseline in the SELENA SLEDAI Score at Week 24 | -35.8 ± 9.1 | -40.5 ± 8.6 |
| mg/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in Complement C3 at Week 24 | 188.0 ± 51.5 | 4.0 ± 44.3 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in Compliment C3 at Week 24 | 25.8 (13.6 to 55.4) | 3.6 (-25.7 to 33.3) |
| mg/dL | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in Complement C4 at Week 24 | 7.2 ± 1.7 | 2.3 ± 1.4 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in Complement C4 at Week 24 | 76.9 (0 to 133.3) | 40.0 (-46.7 to 200.0) |
| IU/mL | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in Anti-Double-Stranded DNA (Anti-dsDNA)at Week 24 | -33.1 ± 11.1 | -6.0 ± 12.2 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in Anti-dsDNA at Week 24 | -24.0 (-51.4 to 18.4) | 0.0 (-57.2 to 125.8) |
| mmol/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in High Density Lipoproteins (HDL) at Week 24 | 0.1 ± 0.04 | 0.0 ± 0.08 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in HDL at Week 24 | 4.8 (-16.1 to 34.6) | 2.2 (-38.2 to 72.7) |
| mmol/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in Total Cholesterol at Week 24 | 0.1 ± 0.09 | 0.0 ± 0.20 |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in Total Cholesterol at Week 24 | 1.0 (-17.2 to 20.9) | 1.6 (-36.3 to 45.7) |
| Percentage | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Median Percent Change From Baseline in Triglycerides at Week 24 | -4.9 (-46.9 to 183.0) | 4.5 (-59.4 to 120.6) |
| mmol/L | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Absolute Change From Baseline in Triglycerides at Week 24 | -0.1 ± 0.14 | -0.0 ± 0.15 |
Collected over Up to 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab SC Q2WKS | — | 2/28 (7.1%) | 19/28 (67.9%) |
| Belimumab SC 3X/WK | — | 4/28 (14.3%) | 18/28 (64.3%) |
| Event | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/28 | 0/28 |
| BradycardiaCardiac disorders | 0/28 | 1/28 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 1/28 | 0/28 |
| CellulitisInfections and infestations | 0/28 | 1/28 |
| GastroenteritisInfections and infestations | 0/28 | 1/28 |
| Pneumococcal sepsisInfections and infestations | 0/28 | 1/28 |
| PyelonephritisInfections and infestations | 1/28 | 0/28 |
| Subcutaneous abscessInfections and infestations | 0/28 | 1/28 |
| Event | Belimumab SC Q2WKS | Belimumab SC 3X/WK |
|---|---|---|
| HeadacheNervous system disorders | 6/28 | 5/28 |
| NasopharyngitisInfections and infestations | 5/28 | 0/28 |
| Upper respiratory tract infectionInfections and infestations | 5/28 | 3/28 |
| DiarrhoeaGastrointestinal disorders | 4/28 | 1/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/28 | 4/28 |
| NauseaGastrointestinal disorders | 2/28 | 3/28 |
| FatigueGeneral disorders | 3/28 | 2/28 |
| SinusitisInfections and infestations | 0/28 | 3/28 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/28 | 3/28 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/28 | 2/28 |
| Age Continuous(years) | Belimumab SC Q2WKS | Belimumab SC 3X/WK | Total |
|---|---|---|---|
| Mean | 39.2 ± 11.5 | 40.9 ± 13.1 | 40.1 ± 12.2 |
| Sex: Female, Male(Participants) | Belimumab SC Q2WKS | Belimumab SC 3X/WK | Total |
|---|---|---|---|
| Female | 26 | 27 | 53 |
| Male | 2 | 1 | 3 |
| Region of Enrollment(participants) | Belimumab SC Q2WKS | Belimumab SC 3X/WK | Total |
|---|---|---|---|
| United States | 24 | 25 | 49 |
| Mexico | 4 | 3 | 7 |
The record gives a start of Oct 2008, a primary completion of Oct 2009 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →